Skip to main content

Table 9 (A) Quality of life of non-metastatic gastric cancer patients, (B) Median difference before–after of quality of Life

From: A randomized, double-blind, placebo-controlled investigation of BCc1 nanomedicine effect on survival and quality of life in metastatic and non-metastatic gastric cancer patients

  Mean
(before)
Std.
deviation
Std.
error mean
P-value Mean
(after)
Std.
deviation
Std.
deviation
P-value
(A) Quality of life in patients with non-metastatic gastric cancer
Global quality
(BCc1 nanomedicine)
40.75 9.013 1.840 0.118 38.46 9.532 9.013 0.200
Global quality
(Placebo)
47.11 12.009 2.831 0.200 50.11 14.046 12.009 0.200
  Mean* Std. deviation Std. error mean P-value
(B) Median difference (beforeafter) of quality of life
Quality of BCc1
(before–after)
2.29 5.497 1.122 0.053
Quality of Placebo
(before–after)
− 3 12.009 2.831 0.038
  1. * Higher score show better global quality of life